Krsnaa Diagnostics Reports All-Time High Quarterly PAT and Strong Revenue Growth for Q2 FY26
Krsnaa Diagnostics reported record Q2 FY26 PAT of ₹23.9 crore, up 22% Y-o-Y, with revenue growing 11%. Retail business surged 60% Q-o-Q, driven by network expansion and strong margins.
The announcement contains strong financial results, including record PAT and significant revenue growth, alongside positive operational developments and future expansion plans. These factors are highly material and likely to have a substantial positive impact on investor perception and stock performance.
The company reported strong financial performance with an all-time high quarterly PAT, significant revenue growth, and improved margins. Operational expansion, including increased accreditations and retail business growth, further contributes to a positive outlook.
* Krsnaa Diagnostics Limited announced its Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2025, through an Investor Presentation. * The company achieved an all-time high Quarterly Profit After Tax (PAT) of ₹23.9 crore (INR 239 million) in Q2 FY26, marking a 22% year-on-year increase from ₹19.6 crore (INR 196 million) in Q2 FY25. * Revenue from operations grew by 11% year-on-year to ₹206 crore (INR 2,060 million) in Q2 FY26 from ₹186.3 crore (INR 1,863 million) in Q2 FY25. * EBITDA increased by 18% to ₹60.2 crore (INR 602 million) in Q2 FY26 from ₹50.9 crore (INR 509 million) in Q2 FY25, with EBITDA margin improving by 221 basis points to 29%. * Earnings Per Share (EPS) rose by 24% to ₹7.3 in Q2 FY26 from ₹5.9 in Q2 FY25. * Operational highlights include a 60% quarter-on-quarter increase in retail business revenue, with its contribution to group revenue rising from 1% to 8%. * The company expanded its network, reaching 57 NABL accredited pathology labs (up 54%) and 36 NABH accredited radiology centres (up 50%) in Q2 FY26. * Krsnaa Diagnostics served 5.4 million patients in Q2 FY26, a 4% increase year-on-year. * Future expansion plans include achieving over 200 CT/MRI centres upon completion of existing orders and expanding the Rajasthan project to 7 Reference Labs, 41 Mother Labs, 249 Satellite Labs, and over 5,000 Collection Centres.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.